Rhythm Pharmaceuticals (RYTM) Capital Expenditures (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Capital Expenditures data on file, last reported at -$435000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 326.47% year-over-year to -$435000.0 in Q1 2026; TTM through Mar 2026 was $64000.0, a 94.14% decrease from a year earlier, with the FY2025 full-year figure at $397000.0, changed N/A from the prior year.
• Capital Expenditures for Q1 2026 stood at -$435000.0, down from $681000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for RYTM reached as high as $5.2 million in Q3 2025 and fell as low as -$5.4 million in Q2 2025.
• Historically, Capital Expenditures has averaged -$83117.6 across 5 years, with a median of -$102000.0 in 2025.
• Across the five-year window, Capital Expenditures tumbled 2136.67% in 2023 and surged 78825.0% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at -$4.6 million in 2022, then jumped by 100.09% to $4000.0 in 2023, then jumped by 78825.0% to $3.2 million in 2024, then slumped by 78.43% to $681000.0 in 2025, then slumped by 163.88% to -$435000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$435000.0 in Q1 2026, $681000.0 in Q4 2025, and $5.2 million in Q3 2025.